CellSource Co.,Ltd. Logo

CellSource Co.,Ltd.

Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.

4880 | T

Overview

Corporate Details

ISIN(s):
JP3423580004
LEI:
Country:
Japan
Address:
渋谷区渋谷一丁目23番21号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CellSource Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company's core operation involves providing contract processing and storage services for tissues and cells to medical institutions. Its key services include the extraction of adipose-derived stem cells and the preparation of platelet-rich plasma (PRP) from patient-derived samples. By offering these specialized processing services, CellSource enables partner medical facilities to provide advanced regenerative therapies. The company's operations are primarily centered on its regenerative medicine-related business, and it also engages in a consumer-focused business segment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-14 08:30
Board/Management Information
臨時報告書
Japanese 20.3 KB
2025-06-30 10:09
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.7 KB
2025-06-12 08:36
Registration Form
確認書
Japanese 8.7 KB
2025-06-12 08:35
Interim Report
半期報告書-第10期(2024/11/01-2025/10/31)
Japanese 203.7 KB
2025-06-12 08:33
Share Issue/Capital Change
臨時報告書
Japanese 30.6 KB
2025-01-31 07:37
Governance Information
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 22.6 KB
2025-01-31 07:36
Registration Form
確認書
Japanese 8.7 KB
2025-01-31 07:35
Registration Form
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 1.0 MB
2025-01-31 07:32
Post-Annual General Meeting Information
臨時報告書
Japanese 24.9 KB
2024-10-31 07:06
Board/Management Information
臨時報告書
Japanese 19.3 KB
2024-06-13 08:07
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-06-13 08:05
Quarterly Report
四半期報告書-第9期第2四半期(2024/02/01-2024/04/30)
Japanese 212.9 KB
2024-03-11 07:04
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-11 07:03
Quarterly Report
四半期報告書-第9期第1四半期(2023/11/01-2024/01/31)
Japanese 162.2 KB
2024-01-25 08:35
Governance Information
内部統制報告書-第8期(2022/11/01-2023/10/31)
Japanese 22.9 KB

Automate Your Workflow. Get a real-time feed of all CellSource Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CellSource Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CellSource Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.